{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:09:30Z","timestamp":1761109770850},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1157\/13091784","type":"journal-article","created":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T11:33:17Z","timestamp":1154604797000},"page":"453-462","source":"Crossref","is-referenced-by-count":4,"title":["Tratamiento de las hepatitis v\u00edricas (I). Tratamiento de la hepatitis cr\u00f3nica B"],"prefix":"10.1016","volume":"24","author":[{"given":"Armando","family":"S\u00e1nchez-Quijano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Lissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13091784_bib1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection. Natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib2","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"AASLD Practice Guideline: chronic hepatitis B","author":"Lok","year":"2001","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.20110","article-title":"AASLD Practice Guideline. Chronic hepatitis B: Update of recommendations","volume":"39","author":"Lok","year":"2004","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib5","unstructured":"EASL Jury, EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Gen\u00e8ve, Switzerland. Consensus statement (long version). J Hepatol. 2003;39:3-25."},{"key":"10.1157\/13091784_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, Prevention and Management of Hepatitis B Virus Reactivation during Anticancer Therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.510290447","article-title":"Influence of HIV coinfection on chronic hepatitis B in homosexual men","volume":"29","author":"Colin","year":"1999","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1157\/13091784_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.10559","article-title":"Hepatitis B viremia is associated with increase risk of hepatocelular carcinoma in chronics carriers","volume":"72","author":"Tang","year":"2004","journal-title":"J Med Virol"},{"key":"10.1157\/13091784_bib10","unstructured":"Prevention of hepatitis A through active or passive immunization Recommendations of Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:RR-12:1-38."},{"key":"10.1157\/13091784_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.21046","article-title":"Noninvasive Mesasures of Liver Fibrosis","volume":"43","author":"Rockey","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"10.1157\/13091784_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1542-3565(03)00312-4","article-title":"Management of Chronic hepatitis B. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States","volume":"2","author":"Keeffe","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1157\/13091784_bib14","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1056\/NEJMe058119","article-title":"The maze of treatments for hepatitis B","volume":"352","author":"Lok","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/jhep.2001.27834","article-title":"Hepatitis B e antigen-negative chronic hepatitis B","volume":"34","author":"Hadziyannis","year":"2001","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib16","unstructured":"Dieterich DT. Hepatitis B Treatment Strategies. Emerging Data and Clinical Consensus Shold Dictate Care. AGA Perspectives (February\/March 2005). Disponible en: http:\/\/www.gastro.org\/wmspage.cfm?parm1 = 1632. Accedido 26 de marzo de 2006."},{"key":"10.1157\/13091784_bib17","unstructured":"Lok AS. Hepatitis B Treatmment Strategies. HBV Treatment Strategies Should Be Based on Published Data. AGA Perspectives (February\/March 2005). Disponible en: http:\/\/www.gastro.org\/wmspage.cfm?parm1 = 1631. Accedido 26 de marzo de 2006."},{"key":"10.1157\/13091784_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","article-title":"Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy","volume":"37","author":"Lampertico","year":"2003","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-114-8-629","article-title":"Long-term remission of chronic hepatitis B after alpha-interferon therapy","volume":"114","author":"Korenman","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1157\/13091784_bib20","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/gast.1997.v113.pm9352870","article-title":"Long term follow up patients with chronic hepatitis B treated with interferon-alfa","volume":"113","author":"Lau","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1157\/13091784_bib21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/jhep.2003.50208","article-title":"Serum HBV DNA as marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature","volume":"37","author":"Mommeja-Marin","year":"2003","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver diseases","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2003-37584","article-title":"Treatment of HBe-Ag-negative chronic hepatitis B","volume":"23","author":"Hadziyannis","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1157\/13091784_bib24","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1086\/315147","article-title":"Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine","volume":"180","author":"Gauthier","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1157\/13091784_bib25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0168-8278(01)00214-8","article-title":"Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients","volume":"35","author":"Komori","year":"2001","journal-title":"J Hepatol"},{"key":"10.1157\/13091784_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, Prevention and management of hepatitis B Virus Reactivation during Anticancer Therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1157\/13091784_bib28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hep.20970","article-title":"Therapy oh hepatitis B- Viral Supression or Eradication?","volume":"43","author":"Perrillo","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1542-3565(04)00017-5","article-title":"Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B","volume":"2","author":"Kuo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1157\/13091784_bib30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection","volume":"40","author":"Van Bommel","year":"2004","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2005.02.017","article-title":"Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B: a two-year study","volume":"43","author":"Gish","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13091784_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.21055","article-title":"Anti-hepatitis B Efficacy of tenefovir Disoproxil Fumarate in HIV-Infected Patients","volume":"43","author":"Benhamou","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecarvir and lamivudina for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib34","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudina for patients with HBeAg-Negative Chronic Hepatitis C","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib35","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudina and the combination for HBe-Ag-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib36","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long-term therapy with adefovir dipovixil for HBeAg-negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13091784_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13091784_bib38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alfa-2a (40 Kd): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepatitis"},{"key":"10.1157\/13091784_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2893.2004.00556.x","article-title":"Sustained response after a 2-year course of lamivudina treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"11","author":"Fung","year":"2004","journal-title":"J Viral Hepatol"},{"issue":"Suppl 1","key":"10.1157\/13091784_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2005-915645","article-title":"Molecular virology and the development of resistant mutant: implications for therapy","volume":"25","author":"Locarnini","year":"2005","journal-title":"Sem Liver Dis"},{"key":"10.1157\/13091784_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistenace in patients with chronic hepatitis B","volume":"9","author":"Locami","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1157\/13091784_bib42","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergences of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudina","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemoter"},{"key":"10.1157\/13091784_bib43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictor of HBeAg loss after lamivudine treatment for chronic hepatitis B","volume":"35","author":"Perrillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13091784_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multicenter Unites States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation. The Lamivudine North American Transplant Group","volume":"33","author":"Perrillo","year":"2001","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1157\/13091784_bib47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"(The EEC Jury). Short Statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1157\/13091784_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hep.21033","article-title":"Growing importance of liver disease in HIV-infected persons","volume":"43","author":"Thomas","year":"2006","journal-title":"Hepatology"},{"key":"10.1157\/13091784_bib49","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the longterm outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13091784_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV. Prevalence, AIDS progression response to highly active therapy and increased mortality in the EUROSIDA cohort","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X06738241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X06738241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:41:48Z","timestamp":1683546108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X06738241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0213005X06738241"],"URL":"https:\/\/doi.org\/10.1157\/13091784","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}